The influence of renal function on hydroxyurea pharmacokinetics in adults with sickle cell disease

Jing He Yan, Kenneth Ataga, Sanjeev Kaul, Jeffery S. Olson, Dennis M. Grasela, Samantha Gothelf, Abdulah Kutlar, Eugene Orringer

Research output: Contribution to journalArticlepeer-review

41 Scopus citations


This was an open-label, nonrandomized, 2-center study conducted to assess the influence of renal function on the pharmacokinetics of hydroxyurea in adults with sickle cell disease (SCD). Seventeen patients were divided into 5 groups: normal renal function (n = 7), mild renal impairment (n = 2), moderate renal impairment (n = 3), severe renal impairment (n = 2), and end-stage renal disease (ESRD, n = 3). Except for patients with ESRD, all the patients received a 15-mg/kg single oral dose of hydroxyurea. Patients with ESRD received a 15-mg/kg oral dose of hydroxyurea on 2 occasions. Blood and urine samples were collected for the assessment of hydroxyurea pharmacokinetics. The results indicate that the systemic exposure increases and the urinary recovery decreases as the degree of renal insufficiency worsens. On the basis of the exposure and the apparent clearance from the current and 2 historical studies, the authors have proposed an initial dosing regimen of hydroxyurea (7.5 mg/kg/day) for SCD patients with CLCR <60 mL/min. This dosing strategy is anticipated to provide a safe dose for SCD patients with renal impairment.

Original languageEnglish (US)
Pages (from-to)434-445
Number of pages12
JournalJournal of Clinical Pharmacology
Issue number4
StatePublished - Apr 2005


  • Hydroxyurea
  • Renal function
  • Sickle cell disease

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'The influence of renal function on hydroxyurea pharmacokinetics in adults with sickle cell disease'. Together they form a unique fingerprint.

Cite this